Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

onemillion2012 Jan. 29 at 7:20 PM

$BCAB last chance to get out of this fraud company.. only dilution and BK around the cornor

0 · Reply

skyrockets_Inc Jan. 29 at 6:41 PM

$BCAB I'm assuming BK soon. Wipe out existing shareholders and continue drug development under a new clean sheet company. Seen it happen many times before and this reeks of it. What a trash company

1 · Reply

BIOCARP Jan. 29 at 6:25 PM

$BCAB When the 8K form takes so long to come out (tomorrow, Friday, is the deadline), it's a bad sign... Bad news, a harbinger. The ratio will be 1:20, the maximum, with the risk that the market anticipates possible dilution. Remember that the Board of Directors was authorized up to $200 million on January 12th to implement dilution up to that limit when they deem it necessary. Jay, take the money and run to China!

1 · Reply

BIOCARP Jan. 29 at 6:18 PM

$BCAB Note: I block all the idiots who get on my nerves. I don't talk to anyone. I express my ideas, sometimes in a bullish way and other times in a bearish way, depending on what I feel like. So ignore me and respect me. I also block the absurd ones who just talk nonsense. I don't want a forum full of clowns who don't have a clue about the stock market.

0 · Reply

BIOCARP Jan. 29 at 5:03 PM

$BCAB What does it mean that the 8-K announcement has to be released tomorrow? This is key: The market KNOWS that: Either they release it tomorrow Or they fail to do so (very unlikely) Therefore: Volatility will increase Overnight risk is high This explains: Why money isn't flowing in Why the gains aren't holding Why it continues to trickle down What NOT to do today (very important) Don't buy to hold overnight Don't anticipate "it's sure to be good tomorrow" Don't buy just because "it's already dropped quite a bit" That would be betting on the announcement, not trading.

0 · Reply

jackabe Jan. 29 at 4:22 PM

$BCAB That directed towards me coco I've been buying and selling afor a couple of weeks not done to bad thanks.Well apart from today thus far but then that just small punt to see if anything positive landed premakt Not sure I'll be in ot over the weekend tho but hey ho who knows The fat lady still squeaking Hiw you getting on 😘

0 · Reply

onemillion2012 Jan. 29 at 3:41 PM

$BCAB $5 next week😄

1 · Reply

BIOCARP Jan. 29 at 3:00 PM

$BCAB Losing $0.30 will trigger stop orders... watch out!

0 · Reply

BIOCARP Jan. 29 at 2:59 PM

$BCAB Well then... buy it so that when the voting results come in, the disastrous 1:20 predilution ratio will plummet out of the market, leaving you trapped inside with no way out... very clever. Keep following advice.

0 · Reply

jackabe Jan. 29 at 12:20 PM

$BCAB Friday deadline for results of vote looming are they going to wait to drop it after hours...... Give everyone the weekend to digest it b4 the mass selling starts or buying No news is good news or maybe not in this case....

1 · Reply

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Nov 21, 2025, 12:25 AM EST - 2 months ago

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Nov 13, 2025, 6:51 PM EST - 2 months ago

BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 2 months ago

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

$BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas$

Nov 7, 2025, 9:00 AM EST - 2 months ago

BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

Nov 5, 2025, 8:00 AM EST - 3 months ago

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

Oct 23, 2025, 8:00 AM EDT - 3 months ago

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

$BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025$

Oct 20, 2025, 8:00 AM EDT - 3 months ago

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Oct 3, 2025, 9:00 AM EDT - 4 months ago

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

Sep 8, 2025, 8:00 AM EDT - 5 months ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

Aug 9, 2025, 2:43 AM EDT - 6 months ago

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 6 months ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 4, 2025, 8:00 AM EDT - 6 months ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 7 months ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$

Jul 3, 2025, 8:00 AM EDT - 7 months ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jun 2, 2025, 8:00 AM EDT - 8 months ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

May 6, 2025, 5:55 PM EDT - 9 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 9 months ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Apr 30, 2025, 8:00 AM EDT - 9 months ago

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 9 months ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 24, 2025, 8:00 AM EDT - 10 months ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 10 months ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 6:18 PM EDT - 11 months ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 5:05 PM EDT - 11 months ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 4:05 PM EDT - 11 months ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 20, 2025, 8:00 AM EDT - 11 months ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 19, 2025, 8:00 AM EDT - 11 months ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 4, 2025, 7:34 AM EST - 11 months ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dec 20, 2024, 9:00 AM EST - 1 year ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 1 year ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Nov 9, 2024, 8:53 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Oct 8, 2024, 6:12 AM EDT - 1 year ago

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 7, 2024, 11:29 AM EDT - 1 year ago

BioAtla: Numerous Catalysts Coming In Q4

Oct 4, 2024, 9:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 1 year ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 5:39 PM EDT - 1 year ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

May 29, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 8, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 2, 2024, 10:03 AM EDT - 1 year ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

Apr 24, 2024, 4:35 PM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 26, 2024, 7:21 PM EDT - 2 years ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 4:01 PM EDT - 2 years ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

onemillion2012 Jan. 29 at 7:20 PM

$BCAB last chance to get out of this fraud company.. only dilution and BK around the cornor

0 · Reply

skyrockets_Inc Jan. 29 at 6:41 PM

$BCAB I'm assuming BK soon. Wipe out existing shareholders and continue drug development under a new clean sheet company. Seen it happen many times before and this reeks of it. What a trash company

1 · Reply

BIOCARP Jan. 29 at 6:25 PM

1 · Reply

BIOCARP Jan. 29 at 6:18 PM

0 · Reply

BIOCARP Jan. 29 at 5:03 PM

0 · Reply

jackabe Jan. 29 at 4:22 PM

0 · Reply

onemillion2012 Jan. 29 at 3:41 PM

$BCAB $5 next week😄

1 · Reply

BIOCARP Jan. 29 at 3:00 PM

$BCAB Losing $0.30 will trigger stop orders... watch out!

0 · Reply

BIOCARP Jan. 29 at 2:59 PM

0 · Reply

jackabe Jan. 29 at 12:20 PM

1 · Reply

onemillion2012 Jan. 29 at 10:58 AM

$BCAB Sell before delisting. The need $$$ tl comply with equlity rule. The $5 million jay will send back to Bioatla is not enough

0 · Reply

jackabe Jan. 28 at 9:50 PM

$BCAB should have put buying or selling for balance 🤪

0 · Reply

jackabe Jan. 28 at 9:38 PM

$BCAB potential reason for no one buying well apart from had a dabble do love a punt🤣 Possibly down to this 👇 Material Non-Public Information (MNPI): The final outcome of the reverse split vote is considered MNPI until it is publicly disclosed. Trading on this information would be illegal insider trading

0 · Reply

jackabe Jan. 28 at 9:25 PM

$BCAB Stockholders' Equity Standard: Alternatively, the company can comply by maintaining at least $10 million in stockholders' equity. BioAtla received a deficiency notice in May 2025 because its equity was only $547,000, but the recent $60 million capital raises should have brought them above this $10 million threshold. Mkts with red candles same as the rest of the sector on low volumne And weve already covered the cheeena non old news You lot want to change up the copy and paste board in the office It's getting comical

1 · Reply

jackabe Jan. 28 at 8:25 PM

$BCAB what you on about coco how many institutions have bought in since the deal in Cheeena was done What a clown 🤣

0 · Reply

jackabe Jan. 28 at 8:18 PM

$BCAB 🤣A board full of proffesional clowns duping everyone buy high sell low. The amount of sharechat boards created by portfolio managers is unreal. Not sure if this is one but theres another I'm in and you don need to know nothing about the mkts you can just by and sell to what the majority are saying 🤣

0 · Reply

BIOCARP Jan. 28 at 8:09 PM

$BCAB The great danger, and this you haven't considered, is that with such low capitalization, it's more profitable to absorb it than to invest money in research... and you lose everything... everything....

0 · Reply

BIOCARP Jan. 28 at 8:08 PM

$BCAB The products look amazing and have a lot of potential... Let's hope it doesn't go bankrupt and get bought out by another company for $3 and you lose all your shares... It wouldn't be the first time.

0 · Reply

BIOCARP Jan. 28 at 8:07 PM

$BCAB Now we'll have to see how everything unfolds and if many things become clear. Investors are being mistreated by the company. I sent a couple of emails asking questions and they haven't even replied. They're not defending the share price. Take your money and run!

0 · Reply

BIOCARP Jan. 28 at 8:05 PM

$BCAB And it's not just me or some random person here saying this... the market is saying it with red candles day after day until the RS situation is clarified, the possible 1:20 ratio, and the serious risk of it being removed from the Nasdaq list (because there's also something else that isn't being discussed, which is the market capitalization they're not meeting). And then there's how they're diverting money to other companies owned by Jay in China in his wife's name... as @onemillion2012, @bcabing, and @love_bioatla were saying. Thanks for opening my eyes.

1 · Reply

BIOCARP Jan. 28 at 8:03 PM

$BCAB I used to say the company was amazing... How wrong I was! Don't be fooled! It's pure garbage. @onemillion2012, @bcabing, and @love_biotala have opened my eyes! Financial danger. The products are very good and have a lot of potential... but... it's almost bankrupt. The RS will be approved at the worst possible ratio, 1:20, and there will be dilution as they run out of money. The monthly burn is brutal, especially starting Phase 3... let's see how it goes.

0 · Reply

jackabe Jan. 28 at 7:34 PM

$BCAB the proffesional traders dont want you to know what really drives the mkts.Thats why they blitz the board and drive it down the page It's a well known secrete everythingvyhat happens in the mkts is driven by those 3 drivers Mkts going to crash A fear trade ie buy the dip A correction Etc etc etc etc All can be 1st seen in the US 10 yr treasury.

0 · Reply

Market Cap	19.71M
Revenue (ttm)	11.00M
Net Income (ttm)	-69.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-634.36%
Debt to Equity Ratio	0.00

Volume	2,997,600
Avg Vol	2,203,478
Day's Range	N/A - N/A
Shares Out	63.46M
Stochastic %K	22%
Beta	1.04
Analysts	Sell
Price Target	$10.00